Biosimilars and Cost Dynamics in the US
The emergence of biosimilar erythropoietin drugs has reshaped the US erythropoietin drug market. Biosimilars offer comparable efficacy to original biologics at lower prices, helping healthcare systems manage rising pharmaceutical expenditures.
Insurance providers and hospital formularies increasingly include biosimilars to promote cost savings. Education campaigns have improved physician confidence in these alternatives.
As competition grows, pricing strategies evolve, benefiting patients and payers alike. The expansion of biosimilars marks a significant shift toward affordability and accessibility in the US market.
1 View